Table 6.
Summary of recommendations for clinical use of S. boulardii in adults
| Use for disease | Dose (mg/d) | Duration | Adjunct to | Strength of evidence1 |
| Prevention of antibiotic associated diarrhea | 500-1000 | During antibiotics with additional 3 d to 2 wk after | Nothing | ++++ |
| Prevention of Traveler’s diarrhea | 250-1000 | Duration of trip (3 wk) | Nothing | +++ |
| Enteral nutrition-related diarrhea | 2000 | 8-28 d | Nothing | ++ |
| H. pylori symptoms | 1000 | 2 wk | Standard triple therapy | ++ |
| Treatment of Clostridium difficile infections | 1000 | 4 wk | Vancomycin or metronidazole | + |
| Acute adult diarrhea | 500-750 | 8-10 d | Nothing | + |
| Inflammatory bowel disease | 750-1000 | 7 wk to 6 mo | Mesalamine | + |
| Irritable bowel syndrome | 500 | 4 wk | Nothing | + |
| Giardiasis | 500 | 4 wk | Metronidazole | + |
| HIV-related diarrhea | 3000 | 7 d | Nothing | + |
1
Strength of evidence, + (weak, needs more randomized controlled trials) to ++++ (strong, efficacy and safety are evidence based from numerous large randomized controlled trials).